- The 2001 Bethesda System neither promotes nor discourages the use of ancillary testing in conjunction with cervical cytology; however the workshop forum group members recognized the need to develop guidelines for reporting results of HPV testing and other assays that might be implemented in the future.
- The test method should be described and the results reported in a manner understandable to the clinician.
- There are various models for reporting ancillary test data based on the combination of cytology and ancillary test results. Laboratories and clinicians should communicate their expectations regarding reporting of ancillary test results and inclusion of clinical management suggestions.
HPV results may be reported:
- as a result only;
- as a result associated with clinical management recommendations;
- as a result plus a probabilistic statement regarding the risk of an underlying CIN 2/3 (Probabilistic reporting model);
- as a final definitive interpretation that reflects both the cytomorphology and the HPV status (Interpretive reporting model).
Sample Reports: Refer to published Bethesda Atlas ( )